• Oxford Nanopore Chooses New CEO With Diagnostics Expertise

    Dec 08 | Diagnostics World News | Oxford Nanopore Technologies named a new CEO this morning, choosing an executive with extensive diagnostics experience. Francis Van Parys, currently CEO of Radiometer, will join Oxford Nanopore and the Board as an Executive Director on March 2, 2026. More

  • How Diagnostics in the Final Frontier Will Affect Those Back Home

    Dec 04 | Diagnostics World | When SpaceX’s Inspiration4 lifted off in 2021, it launched new opportunities for commercial space travel and raised new questions about how a space environment impacts the human body. TrialX believes what we learn about biology in space will not only expand our understanding of extreme environments’ impact on human health but will deepen our understanding of how biomarkers and health data are best gathered and explored at home as well. More

  • Variant Effect Map of Heart Attack Gene Could Aid Early Disease Detection

    Dec 02 | Diagnostics World | Increasing use of genetic testing to identify people at risk for various diseases has led to a skyrocketing number of never-before-seen variants with uncertain connections to those health conditions, making them impractical to investigate one by one as they once were. Clever bench scientists therefore began making all possible variants in genes with a suspected link to a disease or a patient's symptoms about 15 years ago, to determine which ones are most likely pathogenic. More

  • Follow the Money: Baylor College’s Customized Models, Whole-Body Chronic Disease Monitoring, More

    Nov 25 | Diagnostics World | Baylor College of Medicine will continue to create customized cell, fly, and mouse models to study rare genetic diseases; Curve Biosciences will advance the clinical validation and commercialization of their Whole-Body Intelligence platform for chronic disease monitoring; and more. More

  • Philips Extends Partnership with Cortechs.ai, Rapid Diagnostic Sepsis Test, Nucleai, University of Glasgow Collaboration

    Nov 24 | Diagnostics World | Royal Philips extended their partnership with Cortechs.ai; OCEAN Dx completes a clinical evaluation study for its innovative rapid diagnostic test for sepsis; Nucleai and the University of Glasgow announce a collaboration; and more. More

  • Multiple Biological Dimensions In A Single Assay

    Nov 19 | Diagnostics World | Watchmaker Genomics has launched TAPS+, a next-generation technology that unites genetic and epigenetic readouts from the same DNA molecule. By capturing multiple biological dimensions in a single assay, TAPS+ delivers a richer, more comprehensive view of tumor biology, with the power to advance applications in translational oncology, early cancer detection, therapy response monitoring, fragmentomics, and minimal residual disease assessment. More

  • Highlights From Last Week’s AMP Meeting

    Nov 18 | Diagnostics World | The Association for Molecular Pathology hosted its 2025 Annual Meeting & Expo last week. Highlights from some of the research presented at the event include faster molecular tests for dangerous regional fungal infections, new Lyme disease tests, AI tools for improving molecular diagnosis, new use for old DNA samples to understand the evolution of colorectal cancer, and more. More

  • Mind the Gap: Whole Genome Sequencing and Phenotype Prediction

    Nov 14 | Diagnostics World | In a study published this week in Nature, researchers from Illumina and The University of Queensland demonstrated the importance of whole-genome sequencing (WGS) to more fully capture the genetics underlying complex human traits and diseases. More

  • Rethinking Diagnosis: Why Clinical Trials Still Misread Women’s Health

    Nov 12 | Diagnostics World | Even though roughly two-thirds of pivotal studies leading to FDA drug approvals now enroll women at rates aligned with their disease burden, their inclusion has “plateaued." Diagnostic criteria and disease models remain largely male-centered because they don’t take into account of the biological and hormonal rhythms that shape women’s health across their lives. That diagnostic blind spot reverberates throughout drug development. More

  • Grail Veterans Launch AI Liquid Biopsy Company

    Nov 11 | Diagnostics World | Veterans of Illumina and Grail launched Hepta, a biotechnology company using transformer-based AI to read the cell-free DNA (cfDNA) epigenome and detect organ-specific signals of chronic disease. Hepta emerged from stealth with $6.7 million in seed funding. More
View more articles

 
DXX-Industry-spotlight

merck


Custom Diagnostic Antibody Development & Manufacturing Services

Overcome Process Challenges by outsourcing your custom antibody production to us. How partnering with an antibody production expert can improve your assay, accelerate launch, and maintain your manufacturing.

Learn more